Renal Cell Carcinoma
From the Journals
Axitinib/pembrolizumab combo safe, effective against mRCC
At a median of 20.4 months of follow-up, the overall response rate was 73% in an open-label phase 1b dose-finding trial and expansion in 52...
Conference Coverage
ERV expression may predict response to immune checkpoint blockade in ccRCC, other solid tumors
ERV expression may be associated with immune checkpoint pathway activation and response to immune checkpoint therapy in ccRCC.
Conference Coverage
Atezolizumab-bevacizumab combo tops sunitinib as first-line therapy for RCC
With a median follow-up of 15 months, compared with sunitinib, the combination of atezolizumab and bevacizumab prolonged investigator-assessed...
From the Journals
Retroperitoneal lymphadenectomy did not impact OS and DFS for high risk, nonmetastatic renal cell carcinoma
In a secondary analysis of the ASSURE adjuvant trial, there was no relative improvement in overall survival for lymphadenectomy in high-risk RCC...
From the Journals
OS similar among mRCC patients enrolled in clinical trials across different geographic regions
Despite different baseline characteristics, OS was similar among patients enrolled in clinical trials across different geographic regions.
From the Journals
Phase 1 study: Human IL-10 plus checkpoint blockade looks promising in RCC, NSCLC
Pegylated human IL-10 + anti–PD-1 therapy is well tolerated and shows promise for the treatment of both RCC and NSCLC.
From the Journals
In Brazil, few patients get second- and third-line treatment for metastatic RCC
Of 3,990 patients with mRCC, 79% received an appropriate first-line treatment, but only 20% went on to get a second-line agent.
From the Journals
Mutations linked to checkpoint inhibitor response in RCC
Researchers find potential way to predict immunotherapy responsiveness in renal cell carcinoma and other cancers.
News
FDA approves cabozantinib for the frontline treatment of advanced RCC
Approval was based on a 52% reduction in rate of disease progression when compared with treatment with sunitinib.
Conference Coverage
First-in-class glutaminase inhibitor combats anti-PD-1/PD-L1 resistance
NATIONAL HARBOR, MD. – Responses in melanoma patients who were progressing on nivolumab at study entry and who were refractory to multiple prior...
News
FDA approves sunitinib malate as adjuvant treatment for RCC
Sunitinib malate is the first adjuvant treatment approved for patients with renal cell carcinoma.